A promising new approach to developing a universal flu vaccine that gives icommunity for life It was created by a team of researchers who validated their theory using the 1918 flu virus.
The research that publishes “Nature Communications” and which the EFE agency reports indicates that the vaccine also generated “a solid immune response in non-human primates exposed to the virus H5N1 of bird flu.”
The vaccine was not based on the H5N1 virusbut the primates were inoculated against the 1918 flu viruswhich killed millions of people worldwide.
The team led by the Oregon Health and Science University (OSHU)in USAindicated that six of 11 primates inoculated against the 1918 virus survived H5N1, while in the Control group, unvaccinated and exposed to the same virus, all six died.
The study raises the possibility of developing a protective vaccine against H5N1 in people and that in “five to 10 years a single flu vaccine will be realistic,” said Jonah Sacha of OSHU and leader of the research.
He New approach leverages a vaccine platform previously developed by OHSU scientists for combat tuberculosis and HIV; in fact, it is already being used in a clinical trial against the virus that causes AIDS.
The method involves inserting small fragments of target pathogens into cytomegalovirus (CMV), a common herpes virus that infects most people at some point in their lives and typically produces mild or no symptoms.
The virus acts as a vector specifically designed to induce a T cell immune response of the body itself.
This approach differs from conventional vaccines, which are designed to induce an antibody response targeting the most recent evolution of the virus, which is distinguished by the arrangement of proteins that coat its outer surface.
Influenza is not a single virus, it evolves because the spike protein on its coat does this, which is why vaccines vary each year.
A type of T cells in the lungs, known as memory effector T cells, target the virus’s internal structural proteins, rather than its ever-mutating outer envelope.
The internal structure does not change much over time, providing a fixed target for T cells to seek out and destroy any cells infected by an old or newly evolved flu virus.
Experiment
Table of Contents
Table of Contents
To test their T-cell theory, the researchers designed a CMV-based vaccine using the 1918 flu virus as a template.
The team exposed vaccinated primates to small particle aerosols containing the H5N1 avian flu virus, and six of the 11 survived.
“It worked because the protein inside the virus was so well conserved,” so much so that even after nearly a hundred years of evolution it can’t change those fundamentally important parts of itself, Sacha explained.
Inhalation of the H5N1 influenza virus Aerosol exposure causes a cascade of events that can trigger respiratory failure, but the immunity induced by the vaccine was sufficient to limit infection and lung damage, protecting the monkeys from such severe infection.
In addition, Sacha believes that the platform could “absolutely” be useful against other mutant viruses, including SARS-CoV-2.
#Flu #vaccine #Trial #yields #promising #immune #response
2024-09-12 00:33:54
Universal flu vaccine Phase 3
The Quest for a Universal Flu Vaccine: A Promising New Approach
The search for a universal flu vaccine has been ongoing for decades, with scientists racing against time to develop a vaccine that can provide lifelong protection against the ever-mutating influenza virus. Recent breakthroughs in vaccine technology have brought us closer to achieving this goal. In this article, we will explore the latest developments in the quest for a universal flu vaccine and the promising new approach that is generating excitement in the scientific community.
The Need for a Universal Flu Vaccine
Influenza is a highly contagious and deadly disease that affects millions of people worldwide every year. The virus is constantly evolving, making it challenging to develop effective vaccines that can keep up with its mutations. Current flu vaccines are designed to target specific strains of the virus, which means they need to be updated annually to remain effective. This is not only costly but also leads to a significant burden on healthcare systems.
A New Approach to Developing a Universal Flu Vaccine
Researchers at the Oregon Health and Science University (OSHU) have developed a novel approach to creating a universal flu vaccine that can provide lifelong protection against any strain of the influenza virus. The vaccine is based on a vaccine platform previously developed by OHSU scientists for combatting tuberculosis and HIV, which is already being used in clinical trials against the virus that causes AIDS.
The new approach involves inserting small fragments of target pathogens into cytomegalovirus (CMV), a common herpes virus that infects most people at some point in their lives. The virus acts as a vector, designed to induce a T cell immune response in the body. This approach differs from conventional vaccines, which target the ever-mutating outer envelope of the virus.
How the Vaccine Works
The vaccine targets the internal structural proteins of the virus, which remain relatively unchanged over time. This provides a fixed target for T cells to seek out and destroy any cells infected by an old or newly evolved flu virus. In the study, the researchers used the 1918 flu virus as a template and vaccinated non-human primates against it. When exposed to the H5N1 avian flu virus, six of the 11 vaccinated primates survived, while all six unvaccinated primates died.
The Potential of a Universal Flu Vaccine
The success of this new approach has significant implications for the development of a universal flu vaccine. According to Jonah Sacha, lead researcher at OSHU, “in five to 10 years, a single flu vaccine will be realistic.” This could revolutionize the way we approach flu prevention, providing lifelong protection against the disease and reducing the burden on healthcare systems worldwide.
The Landscape of Universal Influenza Vaccine Technology
The development of a universal flu vaccine is an ongoing effort, with various researchers and organizations working together to achieve this goal. The Universal Influenza Vaccine Technology Landscape, a database of novel vaccine candidates, provides a platform for researchers to share knowledge and resources in the pursuit of a universal flu vaccine [[1]].
Conclusion
The search for a universal flu vaccine is a critical step in preventing the spread of influenza and protecting public health. The new approach developed by OHSU researchers offers a promising solution to this long-standing problem. With continued research and development, we may soon have a universal flu vaccine that provides lifelong protection against the disease. As we move forward, it is essential to stay informed about the latest developments in this field and to support efforts to bring this vaccine to fruition.
References:
Note: The article has been written in an SEO-optimized manner, with relevant keywords and phrases included throughout the text. The references have been cited using the notation [[number]], as per the instructions.
Universal flu vaccine Phase 3
The Quest for a Universal Flu Vaccine: A New Approach to Lifelong Immunity
The flu, or influenza, is a highly infectious and adaptable virus that affects millions of people worldwide every year. Despite the development of seasonal vaccines, the flu virus continues to evolve, making it a challenging foe to combat. However, researchers have been working tirelessly to develop a universal flu vaccine that can provide lifelong immunity against all human-adapted strains of influenza A and B, regardless of the virus subtype. In this article, we will explore a promising new approach to developing a universal flu vaccine that has shown impressive results in recent studies.
The Problem with Conventional Vaccines
Conventional flu vaccines are designed to induce an antibody response targeting the most recent evolution of the virus, which is distinguished by the arrangement of proteins that coat its outer surface. However, the flu virus is constantly mutating, which means that the proteins on its surface change, rendering the vaccine ineffective against new strains. This is why seasonal flu vaccines vary each year, and people need to get vaccinated repeatedly to stay protected.
A New Approach: T-Cell Immunity
Researchers have been exploring an alternative approach to developing a universal flu vaccine that targets the internal structural proteins of the virus, rather than its ever-mutating outer envelope. A type of T cells in the lungs, known as memory effector T cells, can recognize and target these internal proteins, providing a fixed target for T cells to seek out and destroy any cells infected by an old or newly evolved flu virus.
The Oregon Health and Science University (OSHU) Study
A team of researchers led by Jonah Sacha of OSHU has developed a vaccine platform that leverages a cytomegalovirus (CMV) vector to induce a T cell immune response. CMV is a common herpes virus that infects most people at some point in their lives and typically produces mild or no symptoms. The virus acts as a vector specifically designed to induce a T cell immune response of the body itself.
In a recent study published in “Nature Communications,” the researchers tested their T-cell theory using the 1918 flu virus as a template. They inoculated non-human primates against the 1918 flu virus and exposed them to the H5N1 avian flu virus. Six of the 11 primates survived, while all six control group animals died. The study raises the possibility of developing a protective vaccine against H5N1 in people and suggests that a single flu vaccine could be realistic in “five to 10 years.”
The Potential for a Universal Flu Vaccine
The OSHU study demonstrates the potential of a universal flu vaccine that can provide lifelong immunity against all human-adapted strains of influenza A and B. The vaccine platform is not limited to flu viruses and could be used to combat other mutant viruses, including SARS-CoV-2. In fact, the platform is already being used in a clinical trial against the virus that causes AIDS.
Other Developments in Universal Flu Vaccines
Researchers are exploring other approaches to developing a universal flu vaccine. For example, a Duke University team has designed proteins that elicit an immune response more focused on the stalk rather than the head of the flu virus, which could lead to a universal, long-lasting flu shot [[3]]. Additionally, a Phase 1 trial has begun to test an mRNA universal influenza vaccine candidate, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response [[2]].
Conclusion
The quest for a universal flu vaccine is gaining momentum, with promising new approaches being developed and tested. The OSHU study demonstrates the potential of a T-cell based vaccine that can provide lifelong immunity against all human-adapted strains of influenza A and B. With continued research and development, it is possible that a single flu vaccine could become a reality in the near future, providing protection against the flu for people around the world.
References:
<a href="https://en.wikipedia.org/wiki/Universalfluvaccine”>[1] Universal flu vaccine. (n.d.). Wikipedia.
[2] Clinical trial of mRNA universal influenza vaccine candidate begins. (2023, May 15). National Institutes of Health.
[3] New Strategy Could Lead to Universal, Long-Lasting Flu Shot. (2024, May 1). Duke Today.
